Total Payments
$16,666
2023 Payments
$414.67
Companies
10
Transactions
21
Medicare Patients
614
Medicare Billing
$176,224
Payment Breakdown by Category
Consulting$11,918 (71.5%)
Other$2,450 (14.7%)
Travel$1,412 (8.5%)
Food & Beverage$681.52 (4.1%)
Education$205.28 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $11,918 | 3 | 71.5% |
| Grant | $2,000 | 2 | 12.0% |
| Travel and Lodging | $1,412 | 7 | 8.5% |
| Food and Beverage | $681.52 | 6 | 4.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $450.00 | 1 | 2.7% |
| Education | $205.28 | 2 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Imbrium Therapeutics L.P. | $5,568 | 1 | $0 (2020) |
| Amgen Inc. | $3,948 | 2 | $0 (2017) |
| Spectrum Pharmaceuticals Inc. | $3,841 | 8 | $0 (2017) |
| SANOFI-AVENTIS U.S. LLC | $2,000 | 2 | $0 (2022) |
| GENZYME CORPORATION | $675.33 | 3 | $0 (2018) |
| National Marrow Donor Program | $238.18 | 1 | $0 (2023) |
| Adaptive Biotechnologies Corporation | $139.28 | 1 | $0 (2023) |
| Celgene Corporation | $115.85 | 1 | $0 (2019) |
| Incyte Corporation | $103.07 | 1 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $37.21 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $414.67 | 3 | National Marrow Donor Program ($238.18) |
| 2022 | $2,000 | 2 | SANOFI-AVENTIS U.S. LLC ($2,000) |
| 2020 | $5,671 | 2 | Imbrium Therapeutics L.P. ($5,568) |
| 2019 | $115.85 | 1 | Celgene Corporation ($115.85) |
| 2018 | $86.48 | 1 | GENZYME CORPORATION ($86.48) |
| 2017 | $8,378 | 12 | Amgen Inc. ($3,948) |
All Payment Transactions
21 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/16/2023 | National Marrow Donor Program | — | Travel and Lodging | In-kind items and services | $238.18 | General |
| 08/21/2023 | E.R. Squibb & Sons, L.L.C. | ABECMA (Biological) | Education | In-kind items and services | $37.21 | General |
| Category: Oncology | ||||||
| 02/01/2023 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $139.28 | General |
| Category: ONCOLOGY | ||||||
| 12/14/2022 | SANOFI-AVENTIS U.S. LLC | — | Grant | Cash or cash equivalent | $1,000.00 | General |
| 04/15/2022 | SANOFI-AVENTIS U.S. LLC | — | Grant | Cash or cash equivalent | $1,000.00 | General |
| 02/27/2020 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $103.07 | General |
| Category: Hematology/Oncology | ||||||
| 01/22/2020 | Imbrium Therapeutics L.P. | — | Consulting Fee | Cash or cash equivalent | $5,567.50 | General |
| 12/07/2019 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $115.85 | General |
| Category: Hematology / Oncology | ||||||
| 02/23/2018 | GENZYME CORPORATION | MOZOBIL (Drug) | Food and Beverage | In-kind items and services | $86.48 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2017 | Spectrum Pharmaceuticals Inc. | Evomela (Drug) | Education | Cash or cash equivalent | $168.07 | General |
| Category: Not Applicable | ||||||
| 10/07/2017 | Spectrum Pharmaceuticals Inc. | Evomela (Drug) | Travel and Lodging | Cash or cash equivalent | $142.20 | General |
| Category: Not Applicable | ||||||
| 10/07/2017 | Spectrum Pharmaceuticals Inc. | Evomela (Drug) | Travel and Lodging | In-kind items and services | $79.26 | General |
| Category: Not Applicable | ||||||
| 10/07/2017 | Spectrum Pharmaceuticals Inc. | Evomela (Drug) | Travel and Lodging | Cash or cash equivalent | $64.00 | General |
| Category: Not Applicable | ||||||
| 10/06/2017 | Spectrum Pharmaceuticals Inc. | Evomela (Drug) | Travel and Lodging | In-kind items and services | $326.54 | General |
| Category: Not Applicable | ||||||
| 10/06/2017 | Spectrum Pharmaceuticals Inc. | Evomela (Drug) | Travel and Lodging | In-kind items and services | $56.46 | General |
| Category: Not Applicable | ||||||
| 10/02/2017 | Spectrum Pharmaceuticals Inc. | Evomela (Drug) | Travel and Lodging | Cash or cash equivalent | $504.96 | General |
| Category: Not Applicable | ||||||
| 09/26/2017 | Spectrum Pharmaceuticals Inc. | Evomela (Drug) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: Not Applicable | ||||||
| 04/26/2017 | GENZYME CORPORATION | MOZOBIL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $450.00 | General |
| Category: ONCOLOGY | ||||||
| 02/24/2017 | GENZYME CORPORATION | MOZOBIL (Drug) | Food and Beverage | In-kind items and services | $138.85 | General |
| Category: ONCOLOGY | ||||||
| 02/09/2017 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $3,850.00 | General |
| 02/01/2017 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $97.99 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 157 | 605 | $201,713 | $47,748 |
| 2022 | 5 | 142 | 399 | $152,506 | $38,060 |
| 2021 | 5 | 173 | 613 | $213,392 | $57,889 |
| 2020 | 6 | 142 | 376 | $129,153 | $32,528 |
Total Patients
614
Total Services
1,993
Medicare Billing
$176,224
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 49 | 371 | $83,709 | $23,370 | 27.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 50 | 172 | $91,728 | $19,165 | 20.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 34 | 34 | $21,472 | $3,869 | 18.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 24 | 28 | $4,804 | $1,344 | 28.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 57 | 157 | $80,817 | $17,529 | 21.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 189 | $53,487 | $15,373 | 28.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 21 | 22 | $12,614 | $3,559 | 28.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 19 | 20 | $3,303 | $982.12 | 29.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 11 | 11 | $2,285 | $615.61 | 26.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 53 | 358 | $101,314 | $30,007 | 29.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 58 | 177 | $87,723 | $20,504 | 23.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 30 | 31 | $16,951 | $5,046 | 29.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 18 | 23 | $3,642 | $1,193 | 32.8% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 14 | 24 | $3,762 | $1,139 | 30.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 27 | 190 | $53,770 | $16,214 | 30.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 40 | 100 | $47,710 | $8,748 | 18.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 21 | 21 | $11,386 | $2,931 | 25.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 11 | 12 | $6,350 | $1,937 | 30.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 20 | 23 | $5,413 | $1,510 | 27.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 23 | 30 | $4,524 | $1,187 | 26.2% |
About Dr. Qaiser Bashir, MD
Dr. Qaiser Bashir, MD is a Hematology & Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/30/2007. The National Provider Identifier (NPI) number assigned to this provider is 1972640241.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Qaiser Bashir, MD has received a total of $16,666 in payments from pharmaceutical and medical device companies, with $414.67 received in 2023. These payments were reported across 21 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($11,918).
As a Medicare-enrolled provider, Bashir has provided services to 614 Medicare beneficiaries, totaling 1,993 services with total Medicare billing of $176,224. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Houston, TX
- Active Since 01/30/2007
- Last Updated 01/28/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1972640241
Products in Payments
- Evomela (Drug) $3,841
- MOZOBIL (Drug) $675.33
- clonoSEQ (Device) $139.28
- Pomalyst (Drug) $115.85
- JAKAFI (Drug) $103.07
- ABECMA (Biological) $37.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Houston
Devesh Pandya, M.d, M.D
Hematology & Oncology — Payments: $1.8M
Hematology & Oncology $1.8M
Elias Jabbour, M.d, M.D
Hematology & Oncology — Payments: $1.6M
Hematology & Oncology $1.6M
Dr. Naval Daver, Mbbs, MBBS
Hematology & Oncology — Payments: $983,097
Hematology & Oncology $983,097
Jorge Cortes-Franco, M.d, M.D
Hematology & Oncology — Payments: $927,016
Hematology & Oncology $927,016
Dr. Luis Camacho, M.d., Mph, M.D., MPH
Hematology & Oncology — Payments: $491,819
Hematology & Oncology $491,819
Christopher Flowers, M.d, M.D
Hematology & Oncology — Payments: $320,001
Hematology & Oncology $320,001